title: Lactic acidosis during telbivudine treatment for HBV: a case report and literature review.
abstract: All oral nucleoside analogues against hepatitis B virus, with an exception of telbivudine, have been reported causing lactic acidosis (LA). Here we report the first case of chronic hepatitis B developing severe refractory LA during telbivudine monotherapy. A 36-year-old man of Chinese origin received telbivudine antiviral treatment for chronic hepatitis B. After 11 mo of therapy, he developed anorexia, nausea, and vomiting with mild muscle weakness. The patient was found with elevated serum creatine phosphokinase up to 3683 U/L (upper limit of normal 170 U/L) and marked LA. LA did not resolve immediately following discontinuation of telbivudine. His condition began to improve after hemodialysis treatment for 16 times and usage of glucocorticosteroid. The patient fully recovered after 16 wk of treatment. This is the first documented case with severe LA caused by telbivudine monotherapy. Besides serum creatine phosphokinase, blood lactate level should also be closely monitored in patients receiving telbivudine.
authors.affiliation: Jia-Lin Jin, Piao Hu, Xiao-Yun Huang, Xin-Hua Weng, Ji-Ming Zhang, Department of Infectious Diseases, Huashan Hospital, Fudan University, Shanghai 200040, China.
authors.forename: Jia-Lin
authors.initials: JL
authors.lastname: Jin
authors.forename: Piao
authors.initials: P
authors.lastname: Hu
authors.forename: Jia-Hong
authors.initials: JH
authors.lastname: Lu
authors.forename: Su-Shan
authors.initials: SS
authors.lastname: Luo
authors.forename: Xiao-Yun
authors.initials: XY
authors.lastname: Huang
authors.forename: Xin-Hua
authors.initials: XH
authors.lastname: Weng
authors.forename: Ji-Ming
authors.initials: JM
authors.lastname: Zhang
mesh_terms: D000140:Acidosis, Lactic / Q000139:chemically induced*; D000328:Adult; D000998:Antiviral Agents / Q000009:adverse effects*; D019694:Hepatitis B, Chronic / Q000188:drug therapy*; D006801:Humans; D008297:Male; D028361:Mitochondrial Diseases / Q000139:chemically induced; D009135:Muscular Diseases / Q000139:chemically induced; D000077712:Telbivudine; D013936:Thymidine / Q000009:adverse effects / Q000031:analogs & derivatives*
chemical_list: D000998:Antiviral Agents; D000077712:Telbivudine; D013936:Thymidine
keywords: Adverse effects; Hepatitis B virus; Lactic acidosis/hyperlactatemia; Nucleoside analogue; Telbivudine
references.citation: Hepatology. 2009 May;49(5 Suppl):S185-95
references.pmid: 19399802
references.citation: N Engl J Med. 1995 Oct 26;333(17):1099-105
references.pmid: 7565947
references.citation: J Clin Gastroenterol. 2009 Nov-Dec;43(10):1008-10
references.pmid: 19461528
references.citation: Nat Clin Pract Nephrol. 2006 Feb;2(2):109-14; quiz 115
references.pmid: 16932402
references.citation: HIV Med. 2010 Feb;11(2):121-9
references.pmid: 19702629
references.citation: Dig Liver Dis. 2011 Dec;43(12):1027-8
references.pmid: 21782535
references.citation: J Viral Hepat. 2012 Oct;19(10):732-43
references.pmid: 22967105
references.citation: Pediatr Pulmonol. 2007 Jan;42(1):41-50
references.pmid: 17123315
references.citation: Int J STD AIDS. 2000 Sep;11(9):611-6
references.pmid: 10997508
references.citation: AIDS. 2008 Jul 11;22(11):1374-6
references.pmid: 18580619